Radiologically Isolated Syndrome Clinical Trials
A listing of Radiologically Isolated Syndrome medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Found 124 clinical trials
Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing (OVERLORD-MS)
This is a multicenter non-inferiority study, designed to establish non-inferiority of the study treatment rituximab compared with the comparator ocrelizumab for consecutively included patients (male or female) with active relapsing-remitting multiple sclerosis aged 18-60 years.
- 1 views
- 22 Oct, 2022
- 13 locations
Development of a Telehealth Obesity Intervention for Patients With MS: Modifying Diet and Exercise in MS
We will tailor a telehealth obesity intervention for obese patients with MS (figure 2). Half of the patients will be randomly assigned to 24 weekly hour-long group weight loss sessions and 6 monthly individual sessions; half will be assigned to a brief education/Treatment as Usual (TAU) control condition. Participants assigned …
- 9 views
- 07 Oct, 2021
- 1 location
Norwegian Study of Oral Cladribine and Rituximab in Multiple Sclerosis (NOR-MS) (NOR-MS)
The main aim and overall objective of the study is to assess whether rituximab is non-inferior to cladribine for the treatment of relapsing MS. Secondly, the investigators will test specific blood and MRI biomarkers that may contribute to future personalized treatment for MS patients. Furthermore, the investigators want to evaluate …
- 0 views
- 15 May, 2022
- 6 locations
Minocycline in MS: Confirmation of Benefit (MS)
This is an open-label, single-arm clinical trial. Trial participants will include men and women, aged 18-60 years who have had a first demyelinating event within the previous 180 days and who have brain magnetic resonance imaging (MRI) with at least two brain T2 lesions which are at least 3 mm …
- 11 views
- 28 Feb, 2022
- 1 location
Bazedoxifene Acetate as a Remyelinating Agent in Multiple Sclerosis (ReWRAP)
The primary goal of this study is to assess the efficacy of bazedoxifene (BZA) as remyelinating agent in patients with relapsing-remitting multiple sclerosis (RRMS). The investigators will utilize electrophysiologic techniques and magnetic resonance imaging to quantify the effect of treatment in 50 women over the course of 6 months. Participants …
- 80 views
- 06 Apr, 2022
- 1 location
Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis (MoveS-it)
A safety study of ANK-700 in patients with relapsing remitting multiple sclerosis. The study has two parts: Part A - first in human study in which patients receive a single dose of ANK-700 Part B - patients will receive three doses of either ANK-700 or placebo
- 9 views
- 01 May, 2022
- 10 locations
Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis (CLOCK-MS)
The purpose of this study is to better understand the mechanism of action (MoA) of cladribine tablets by exploring the effect on central nervous system (CNS) and blood biomarkers relevant in the relapsing forms of multiple sclerosis (RMS; to include relapsing-remitting MS [RRMS] or active secondary progressive MS).
- 1 views
- 07 Oct, 2022
- 4 locations
MitoQ for Fatigue in Multiple Sclerosis (MS) (MitoQ)
The purpose of this study is to determine whether MS patients who receive Oral mitoquinone (MitoQ) have less fatigue than those receiving a placebo. A comparison between patient's fatigue scored at baseline and fatigue scored 12 weeks after drug initiation will assess if MitoQ has a significant change in fatigue.
- 2 views
- 06 May, 2022
- 1 location
Use of Audio Recordings of Self-Hypnosis and Meditation for Fatigue Management in Multiple Sclerosis (AUDIO)
The purpose of this study is to assess the effectiveness of two self-guided psychological treatments, Self-Hypnosis (HYP) and Mindfulness Meditation (MM) compared to Treatment as Usual (TAU) for people with multiple sclerosis (MS) and clinically significant fatigue.
- 0 views
- 07 Oct, 2022
- 1 location
Discontinuing Disease-modifying Therapies in Stable Relapsing - Onset Multiple Sclerosis (DOT-MS).
The aim of this study is to identify whether it is possible to safely discontinue treatment in relapsing-onset MS patients who have shown no evidence of active inflammation in the years prior to inclusion clinically and/or radiologically. The secondary objectives address the questions whether the discontinuation of first-line treatment has …
- 0 views
- 26 Jan, 2021
- 1 location